Published in AIDS Weekly, June 26th, 2006
Synergistic antiviral activity between the two agents was demonstrated against both laboratory and clinical strains of HIV-1 using conventional in vitro techniques. The research demonstrates TNX-355's ability to act synergistically with another drug targeting an early step in the entry cascade and supports the strategy of combining therapies directed at sequential steps of the viral-entry process. Agents are defined as synergistic when the activity seen in combination is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.